IBEX Technologies Inc. (OTCPK: IBXN.F)
Health Care · Biotechnology · CA
$—
— today · — 1Y
IBEX Technologies Inc. (OTCPK: IBXN.F) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores IBEX Technologies Inc. across four factors: quality 77/100, growth 54/100. Its strongest factor is quality.
IBXN.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $5.98M
- P/E
- —
- EPS
- 0.15
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 9
- Next earnings
- —
About IBEX Technologies Inc.
IBEX Technologies Inc., through its subsidiaries, manufactures and markets enzymes for biomedical use in Canada, the United States, Germany, the United Kingdom, and internationally. It offers a portfolio of recombinant glycosaminoglycan lyases, including Heparinase I, Heparinase II, Heparinase III, Chondroitinase AC, and Chondroitinase B; collagen ELISAs for the study of synthesis and degradation of connective tissue components; collagen antibodies; and diamine oxidase liquid. The company also manufactures and markets a range of arthritis assays, which are used in osteoarthritis research. In addition, it provides lyophilization services for making disposable medical device components; and custom fermentation and contract manufacturing services. It serves manufacturers of medical devices, quality control labs, low molecular weight heparin manufacturers, and academic research institutions. IBEX Technologies Inc. was incorporated in 1972 and is based in Montreal, Canada.
- ISIN
- CA4489375085
- Founded
- 1972
- Listed since
- Aug 13, 1996
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.45 | -0.57% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.67 | +0.31% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $145.57 | -0.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.80 | -0.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $824.34 | -1.16% |
| argenx SEENXTBR: ARGX | $65.85B | €867.40 | -3.84% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $137.35 | -5.33% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.